Davis LE, et al. - Via involving 42 patients from 12 centers between September 2014 and May 2018, researchers tested the assumption that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. Data reported that median PFS was significantly improved with regorafenib compared to placebo. The research met its primary endpoint in patients with progressive metastatic osteosarcoma, showing regorafenib activity. For patients with relapsed metastatic osteosarcoma, regorafenib should be considered as a treatment option.